Annual Report for the Financial Year 2024-25.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bharat Parenterals Limited has submitted its Annual Report for FY 2024-25 along with the Notice of its 32nd AGM scheduled for September 26, 2025 via video conferencing. On a standalone basis, total income rose about 20% to ₹31,868.20 lakhs from ₹26,602.46 lakhs in FY24, with net profit after tax at ₹2,645.36 lakhs (vs ₹2,259.37 lakhs) and EPS of ₹40.36. The Board has recommended a final dividend of ₹1.00 per share. Consolidated results turned to a loss of ₹4,367.53 lakhs due to initial losses at subsidiary Innoxel Lifesciences, even as consolidated revenue grew to ₹35,200.07 lakhs. During the year, the company raised ₹98.15 crore through a first-ever preferential allotment, acquired 100% of Varenyam Healthcare and additional stake in Varenyam Biolifesciences (making both wholly-owned subsidiaries), and raised its holding in Innoxel Lifesciences from 51% to 55.89%.
Routine annual report submission with no immediate price action expected; investors gain a comprehensive view of FY25 performance (strong standalone growth, weak consolidated numbers due to subsidiary drag), the new ₹98.15 cr capital infusion, expansion of the group structure, and a modest ₹1 per share dividend.